Live Chat

FDA Requires Revised Warning for Actos

Type 2 diabetes patients should be aware that in 2011 the Food and Drug Administration (FDA) issued a warning to patients, health care providers, and the public in which it advised that medical research had concluded that Actos (pioglitazone) consumption had been linked to adverse health effects. Specifically, researchers determined that patients who consumed pioglitazone treatments for more than one year were as much as 40 percent more likely to develop bladder cancer.

 

Have you or a loved one taken pioglitazone-based drugs for an extended period of time? You may be at risk of serious injury as a result. Fortunately, you may have a valid legal claim worth pursing. In fact, thousands of victims have filed suit in federal or state court on the basis of the relationship between Actos and bladder cancer.

 

For your free consultation and to find out how you should move forward, contact the dedicated professionals at the law firm Fears Nachawati. Just call 1.866.545.8364 or email mn@fnlawfirm.com. We’re ready to fight for you!

Categories
Drug Litigation

FDA Requires Revised Warning for Actos